STAT3α |
Signal Transducer and Activator of Transcription 3α |
STAT3β |
Signal Transducer and Activator of Transcription 3β |
STAT1 |
Signal Transducer and Activator of Transcription 1 |
STAT2 |
Signal Transducer and Activator of Transcription 2 |
STAT4 |
Signal Transducer and Activator of Transcription 4 |
STAT5a |
Signal Transducer and Activator of Transcription 5a |
STAT5b |
Signal Transducer and Activator of Transcription 5b |
STAT6 |
Signal Transducer and Activator of Transcription 6 |
NTD |
N-terminal domain |
CCD |
Coiled-coil domain |
DBD |
DNA-binding domain |
SH2 |
SRC-homology-2 domain |
TAD |
Carboxyl-terminal transactivation domain |
IFN |
Interferon |
IL |
Interleukin |
JAK1 |
Janus kinase 1 |
JAK2 |
Janus kinase 2 |
Gp130 |
Glycoprotein 130 |
BCL6 |
B cell lymphoma protein 6 |
PI3K |
Phosphoinositide 3 kinase pathways |
MAPK |
Mitogen activated protein kinase pathways |
ERK |
Extracellular receptor kinase pathways |
EGF |
Epidermal growth factor |
FGF |
Fibroblast growth factor |
IGF |
Insulin-like growth factor |
Gp130 |
Glycoprotein 130 |
Tyr705 |
Tyrosine 705 |
PTPs |
Protein tyrosine phosphatases |
PIAS |
Protein inhibitors of activated STAT |
SOCS |
Suppressors of cytokine signaling |
SHP-1/2 |
Src homology region 2 domain-containing phosphatase 1 and 2 |
NSCLC |
Non-small cell lung cancer |
siRNA |
Small interfering RNA |
Rb |
Retinoblastoma protein |
EMT |
Epithelial-to-mesenchymal transition |
Twist1 |
Twist-related protein 1 |
bHLH |
Basic helix-loop-helix |
E-cadherin |
Epithelial cadherin |
N-cadherin |
Neural cadherin |
MMPs |
Matrix metalloproteinases |
HIF1α |
Hypoxia-inducible factor-1α |
VEGF |
Vascular endothelial growth factor |
PD-L1 |
Programmed death-ligand 1 |
NPCs |
Neural precursor cells |
PTC |
Papillary thyroid carcinoma |
TPO |
Thyroid peroxidase |
Snail1 |
Snail Family Transcriptional Repressor 1 |
GSK |
Glycogen synthase kinase |
HNSCCs |
Head and neck squamous cell cancer cell lines |
DLTs |
Dose limiting toxicities |
FDA |
U.S. Food and Drug Administration |
TUNEL |
Transferase-mediated dUTP nick-end labeling |
AML |
Acute Myelogenous Leukemia |
GVHD |
Graft versus host disease |
ORR |
Objective response rate |
OSCC |
Oral squamous cell carcinoma |
RT-PCR |
Reverse transcription-polymerase chain reaction |
ELISA |
Enzyme-linked immunosorbent assay |
TKIs |
Tyrosine kinase inhibitors |
HCC |
Human hepatocellular carcinoma |
HepPten−
|
Hepatocyte-specific deletion of Pten |
cPR |
Confirmed partial response |
RECIST |
Response Evaluation Criteria in Solid Tumors |
CLL |
Chronic Lymphocytic Lymphoma |
BBI608 |
Napabucasin |
SH2 |
Src homology region 2 |
Shp1 |
Domain-containing phosphatase 1 |
TKI258 |
Dovitinib |
FGFR1 |
Fibroblast growth factor receptor 1 |
FGFR2 |
Fibroblast growth factor receptor 2 |
FGFR3 |
Fibroblast growth factor receptor 3 |
HBCx2 |
Xenograft model |
siRNAs |
Small interfering RNAs |
shRNA |
Short hairpin RNA |
RNAi |
RNA interference |
dsRNA |
Double stranded RNA |
Gint4.T-STAT3 |
Glioblastoma a novel aptamer-siRNA chimera |
BTK |
Bruton tyrosine kinase |
3′-UTR |
3′-untranslated region |
NHL |
Non-Hodgkin’s Lymphoma |
IDH |
Isocitrate dehydrogenase enzyme |
IDH1 |
Isocitrate dehydrogenase enzyme 1 |
IDH2 |
Isocitrate dehydrogenase enzyme 2 |